Suvorexant profile looks suitable for chronic use and I assume its side effect data are better due to its shorter t½ than that of the now discontinued almorexant from GSK/Actelion.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.